Limited polymorphism in Plasmodium falciparum ookinete surface antigen, von Willebrand factor A domain-related protein from clinical isolates

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Richards, Jack S ^a,b   MacDonald, Nicholas J ^c   Eisen, Damon P ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b National Institutes of Health ^*  (Australia)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN; VON WILLEBRAND FACTOR;

ALLELE; ANTIGENICITY; ARTICLE; CLONE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHY; HUMAN; IMMUNITY; LIFE CYCLE; MALARIA; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PROTEIN DOMAIN;

ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; BASE SEQUENCE; DNA, PROTOZOAN; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS;

EID: 33746928717     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-55     Document Type: Article

References (20)

1. Moorthy VS, Good KF, Hill AVS: Malaria vaccine developments. Lancet 2004, 363:150-156.
2. Carter R: Spatial simulation of malaria transmission and its control by malaria transmission blocking vaccination. Int J Parasitol 2002, 32:1617-1624.
3. Williamson KC: Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol 2003, 25:351-359.
4. Carter R: Transmission blocking malaria vaccines. Vaccine 2001, 19:2309-2314.
5. Yuda M, Yano K, Tsuboi T, Torii M, Chinzei Y: von Willebrand Factor A Domain-related Protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Mol Biochem Parasitol 2001, 116:65-72.
6. Li F, Templeton TJ, Popov V, Comer JE, Tsuboi T, Torii M, Vinetz JM: Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission. J Biol Chem 2004, 279:26635-26644.
7. Abraham EG, Islam S, Srinivasan P, Ghosh AK, Valenzuela JG, Ribeiro JM, Kafatos FC, Dimopoulos G, Jacobs-Lorena M: Analysis of the Plasmodium and Anopheles transcriptional repertoire during ookinete development and midgut invasion. J Biol Chem 2004, 279:5573-5580.
8. Whittaker CA, Hynes RO: Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol Biol Cell 2002, 13:3369-3387.
9. Gozar MM, Price VL, Kaslow DC: Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun 1998, 66:59-64.
10. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988, 333:74-76.
11. Duffy PE, Kaslow DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 1997, 65:1109-1113.
12. Hafalla JC, Santiago ML, Pasay MC, Ramirez BL, Gozar MM, Saul A, Kaslow DC: Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol Biochem Parasitol 1997, 87:97-99.
13. Eisen D, Billman-Jacobe H, Marshall VF, Fryauff D, Coppel RL: Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. Infect Immun 1998, 66:239-246.
14. Kaslow DC, Quakyi IA, Keister DB: Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol Biochem Parasitol 1989, 32:101-104.
15. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M: Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 1998, 4:772-782.
16. Ya-Ping S, Alpers MP, Povoa MM, Lal AA: Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol Biochem Parasitol 1992, 50:179-180.
17. Eisen DP, Saul A, Fryauff DJ, Reeder JC, Coppel RL: Alterations in Plasmodium falciparum genotypes during sequential infections suggest the presence of strain specific immunity. Am J Trop Med Hyg 2002, 67:8-16.
18. Hisaeda H, Collins WE, Saul A, Stowers AW: Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine 2001, 20:763-770.
19. Kaslow DC: Transmission-blocking vaccines. Chem Immunol 2002, 80:287-307.
20. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.